Psonet

New therapies in development for psoriasis: what changes in clinical research?

Biological drugs have been considered a scientific and clinical progress in the treatment of psoriasis. However, their role can be fully assessed only when randomized controlled trials will compare them with each other and with conventional drugs, and when data efficacy and safety in the long term will become available  

Meanwhile, search for new molecules carries on and in the near future new therapies will become available: some of these drugs are already used in clinical Phase II and III, while others are in early stages of development.

For drugs close to market, it seems desirable to rely on post-marketing evaluation systems: studies of efficacy and long-term safety, comparison and for assessing outcomes (end point) clinically relevant outcomes, not surrogates.

Here you can find an overview of the state of the art of these new molecules. Information on clinical trials in progress will be regularly updated.

Mechanism	Compound	Administration route	Phase	Sponsor
JAK inhibitor	ABT-494 Upadacitinib	Oral	III	AbbVie
	CF101 piclidenoson	Oral	III	Can-Fite BioPharma
For Itch	Serlopitant	Oral	III	Menlo Therapeutics Inc.
IL-23 inhibitor	Mirikizumab	Subcutaneous	III	Eli Lilly and Company
	MC201	Topical	II	Drug Delivery Solutions Ltd.
Biosimilar	BI 695501	Subcutaneous	III	Boehringer Ingelheim
IL-17 inhibitor	BCD085	Subcutenaous	III	Biocad
ROCK2 inibitor	KD025	Oral	II	Kadmon Corporation, LLC
IL-17A, IL-17F inhibitor	M1095 nanobody	Subcutaneous	IIb	Bond Avillion 2 Development LP
Phytotherapy	TC cream	Topical	II	Psoriasis Research Institute of Guangzhou
Supplement	Psorax35	Oral		Arctic Nutrition AS
Anthracene derivative	Anthralin	By etosome ance liposome		Assiut University
	Enstilar® aereosol foam	Topical		LEO Pharma
RORg agonist	AZD0284	Oral	I	AstraZeneca
Hormone	ACTHar	Topical	I	IRIS Research and Development, LLC
Tyk2 inhibitor	BMS-986165	Oral	III	Bristol-Myers Squibb
Monoclonal antibody	Bimekizumab		III	UCB Biopharma S.P.R.L.
	Ultrasound			University of Cagliari
	Fecal microbiota transplantation	By gastroscopy		Odense University Hospital
IL-23 inhibitor	SCH900222 tildrakizumab	Subcutaneous	III	Merck Sharp & Dohme Corp.
	BI 655066/ABBV-066 (Risankizumab)	Subcutaneous	III	AbbVie
	SPA therapy		III	Association Francaise pour la Recherche Thermale
JAK inhibitor	PF-06700841	topical	IIb	Pfizer

Read more

You can find more information about ongoing clinical trials and drugs in development at the following addresses:

http://www.clinicaltrials.gov/

https://www.psoriasis.org/drug-pipeline

http://controlled-trials.com/ 

http://www.who.int/ictrp/en/

http://www.anzctr.org.au/default.aspx